TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24886116
Drug: Behavioural activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural activation alone (treatment as usual)
Study: 23450712
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (CBTI) delivered in up to eight weekly telephone sessions (CBTI-Phone, n = 15)
Study: 18490498
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin alfa
Study: 19727208
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G-CSF)
Study: 8648396
Drug: CSFs (GM-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSFs (GM-CSF or G-CSF) administered before or during induction therapy and following chemotherapy until neutrophil recovery
Study: 3918430
Drug: Microbial beta-galactosidases
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbial beta-galactosidases added to 360 ml of cow milk containing 18 g of lactose
Study: 24001105
Drug: Pumosetrag 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumosetrag 0.2 mg
Study: 24001105
Drug: Pumosetrag 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumosetrag 0.5 mg
Study: 24001105
Drug: Pumosetrag 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumosetrag 0.8 mg
Study: 22752418
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg(‐1 )day(‐1) ferrous sulfate for 6 months starting at 6 months of age
Study: 17913720
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg every 12 h)
Study: 10712318
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g every 12 h)
Study: 1826046
Drug: Mesoglycan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan (100 mg/day) for six months
Study: 1826046
Drug: Standard anti-platelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-platelet treatment for six months
Study: 6372065
Drug: Trimipramine (Surmontil),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (Surmontil), 50 mg at bedtime
Study: 6372065
Drug: Cimetidine (Tagamet),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (Tagamet), 200 + 200 + 200 + 400 mg/day
Study: 21054750
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ATC
Study: 21054750
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ATC
Study: 21054750
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg 3TC
Study: 18506177
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) administered at 2300 hours
Study: 18506177
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) administered at 1100 hours
Study: 18506177
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (morning administration)
Study: 12853354
Drug: CPT‐11 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 125 mg/m(2), FA 20 mg/m(2) followed by 5‐FU 500 mg/m(2) bolus, weekly for 4 weeks (arm A)
Study: 12853354
Drug: CPT‐11 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 180 mg/m(2) day 1, FA 200 mg/m(2) over 2 h and 5‐FU 400 mg/m(2) bolus and 5‐FU 600 mg/m(2) 22‐h infusion on days 1 and 2, every 2 weeks (arm B)
Study: 12853354
Drug: CPT‐11 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 350 mg/m(2) (days 1 and 43) alternating with FA 20 mg/m(2)/day followed by 5‐FU bolus 425 mg/m(2)/day during 5 days (days 22‐26) (arm C)
Study: 8780093
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTA) injections
Study: 8780093
Drug: Trihexyphenidyl tablets
Normalized name: trihexyphenidyl Oral Tablet
DrugBank: Trihexyphenidyl (DB00376)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trihexyphenidyl tablets plus placebo injection
Study: 1633721
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 1000 mg twice daily
Study: 1633721
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 500 mg twice daily
Study: 1633721
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 10 mg/kg twice daily
Study: 1633721
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 20 mg/kg twice daily
Study: 1633721
Drug: Cefaclor 10
Normalized name: cefaclor 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 10 mg/kg 3-times daily
Study: 1633721
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 500 mg twice daily (elderly subgroup)
Study: 6360751
Drug: Indoprofen 400
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 400 mg i.v.
Study: 6360751
Drug: Pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 30 mg i.v.
Study: 27545050
Drug: SIS augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIS augmentation (Restore Orthobiologic Implant; DePuy, Warsaw, IN, USA)
Study: 27545050
Drug: SIS augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIS augmentation
Study: 17440529
Drug: Kale meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kale meal (150 g)
Study: 17440529
Drug: Kale meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kale meal with potassium oxalate drink (150 g kale + 1.26 g OA)
Study: 17440529
Drug: Spinach meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinach meal (150 g)
Study: 12025521
Drug: Sildenafil (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (initial dose 50 mg taken 1 h before sexual activity for the first 2 weeks, increased to 100 mg or decreased to 25 mg as needed)
Study: 7486360
Drug: Prednisone, 20
Normalized name: PredniSONE, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 20 mg orally every 12 hours for 4 days
Study: 25031133
Drug: Methylphenidate (0.2-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.2-1 mg/kg/d)
Study: 25031133
Drug: Atomoxetine (0.5-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.5-1.2 mg/kg/d)
Study: 2393014
Drug: 400 mL
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL regular coffee
Study: 2393014
Drug: 165 mL
Normalized name: ALCOHOL 165 mL in 250 mL TOPICAL GEL [INSTANT HAND SANITIZER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 165 mL regular coffee
Study: 2393014
Drug: 165 mL
Normalized name: ALCOHOL 165 mL in 250 mL TOPICAL GEL [INSTANT HAND SANITIZER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 165 mL decaffeinated coffee
Study: 2393014
Drug: 165 mL
Normalized name: ALCOHOL 165 mL in 250 mL TOPICAL GEL [INSTANT HAND SANITIZER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 165 mL sodium chloride solution
Study: 23696054
Drug: Tacrolimus plus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus plus steroids (ST)
Study: 21310910
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL, given as three initial treatments with further retreatment as needed)
Study: 17142654
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 1 g iv every six hours plus oral placebo (group A)
Study: 17142654
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen 400 mg po every six hours plus iv placebo (group I)
Study: 14617059
Drug: Iontophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with dexamethazone (3 ml)
Study: 14617059
Drug: Iontophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with saline solution (3 ml)
Study: 8205268
Drug: Alpha-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (50 mg/day)
Study: 8205268
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg/day)
Study: 8889344
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment identification by investigators
Study: 8889344
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment identification by coordinators
Study: 8889344
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment identification
Study: 1889771
Drug: Hemodilution therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution therapy with hydroxyethyl-starch (HAES-steril) combined with pentoxifylline (Trental) for 6 months
Study: 3963860
Drug: MY-1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MY-1 treatment (3 times a week from the 4th postoperative day for 3 weeks)
Study: 27324515
Drug: 2% Chamaemelum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Chamaemelum nobile gel (0.5 mL/3 times a day)
Study: 24338736
Drug: Repaglinide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (3 mg/day for 8 weeks)
Study: 19657792
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone therapy (50 microg estradiol plus 170 microg norethisterone/day)
Study: 16332385
Drug: Tiagabine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (4 mg, two oral doses)
Study: 12556688
Drug: IL-2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 therapy (5 x 10(6) IU twice daily for 5 days: every 4 weeks for three cycles, then every 8 weeks for seven cycles)
Study: 27012873
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g oral glucose
Study: 10641582
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g oral glucose
Study: 11238500
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g oral glucose
Study: 8545223
Drug: High-dose surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose surfactant therapy (beractant, 150 mg (6 mL)/kg, up to four doses, instilled every 6 hours for 20 minutes)
Study: 8545223
Drug: Air placebo
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air placebo (6 mL/kg)
Study: 8545223
Drug: High-dose surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose surfactant therapy
Study: 11910310
Drug: verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 240 mg/day
Study: 6347788
Drug: verapamil 360
Normalized name: verapamil 360 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 360 mg/day
Study: 29336385
Drug: Betamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (4 mg) with/without droperidol (0.625 mg)
Study: 23143523
Drug: Oral antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotic medications
Study: 20646185
Drug: Placebo (PLB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLB) gel (3-6 g/daily)
Study: 8826572
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (divalproex sodium), starting dosage 250 mg bid, titrating to 1000 mg/d if necessary
Study: 6373302
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg sublingual isosorbide dinitrate (ISDN)
Study: 29343232
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 μg∙kg‐1 (Group D2)
Study: 29343232
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg∙kg‐1 (Group D1)
Study: 28222678
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline (Group D0)
Study: 29343232
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg∙kg‐1
Study: 29343232
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 μg∙kg‐1
Study: 24823873
Drug: Exenatide treatment
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide treatment group (n=30)
Study: 24823873
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy group (n=30)
Study: 15798702
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril with bisoprolol
Study: 15798702
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril with carvedilol
Study: 15798702
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril with irbesartan
Study: 12065984
Drug: Posterior long
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior long fusion (surgical treatment)
Study: 12065984
Drug: Nonoperated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperated group (conservative treatment)
Study: 10452757
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP), 800 microg daily for 6 months
Study: 2136866
Drug: Family intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Family intervention combined with drug treatment during hospitalization
Study: 729629
Drug: Furosemide 50
Normalized name: furosemide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 50 mg administered orally
Study: 729629
Drug: Furosemide 50
Normalized name: furosemide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 50 mg administered intravenously
Study: 23706627
Drug: Minocycline 100mg
Normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100mg orally, twice daily for 8 days
Study: 21808963
Drug: Group MKH
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group MKH (midazolam 0.5 mg/kg and ketamine 6 mg/kg)
Study: 21808963
Drug: Group MKL
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group MKL (midazolam 0.25 mg/kg and ketamine 3 mg/kg)
Study: 21808963
Drug: Group M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M (midazolam 0.5 mg/kg)
Study: 19456855
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of amitriptyline
Study: 15326251
Drug: High-dose betaINF-1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose betaINF-1a (60 microg IM/week)
Study: 11241549
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg bicalutamide (Casodex)
Study: 9250639
Drug: EMLA (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (0.15 g/kg, maximum 5.0 g)
Study: 9250639
Drug: TAC (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (0.1 mL/kg, maximum 3.0 mL)
Study: 2900918
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ethyl loflazepate (CM 6912)
Study: 2900918
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ethyl loflazepate (CM 6912)
Study: 23406728
Drug: PEP02 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP02 120 mg/m²
Study: 23406728
Drug: irinotecan 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 300 mg/m²
Study: 19925613
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (600 kcal/d)
Study: 19925613
Drug: Control supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplement (200 kcal/d)
Study: 16914336
Drug: FSC 500/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSC 500/50 microg Diskus, 1 inhalation twice daily + placebo Handihaler, 1 inhalation once daily
Study: 16914336
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg Handihaler, 1 inhalation once daily + placebo Diskus, 1 inhalation twice daily
Study: 16914336
Drug: FSC 500/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSC 500/50 microg Diskus, 1 inhalation twice daily + tiotropium 18 microg Handihaler, 1 inhalation once daily
Study: 9711449
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg/day
Study: 11358726
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen (cetirizine, clarythromycin, topical corticosteroids, hydrating preparations)
Study: 9145693
Drug: Ophthalmic fluorometholone-gentamicin
Normalized name: fluorometholone Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic fluorometholone-gentamicin
Study: 9145693
Drug: Ophthalmic betamethasone-gentamicin
Normalized name: betamethasone / gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic betamethasone-gentamicin
Study: 3064776
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic treatment alone (chemotherapy and/or tamoxifen)
Study: 3101849
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment alone (Control)
Study: 31895881
Drug: wSp 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: wSp 0.1 mg
Study: 31895881
Drug: wSp 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: wSp 0.3 mg
Study: 31895881
Drug: wSp 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: wSp 0.6 mg
Study: 24314016
Drug: Oral prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis with tongue cleaning
Study: 23013513
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of simvastatin and ezetimibe
Study: 12923133
Drug: CDB-2914 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 at doses of 1-100 mg
Study: 12923133
Drug: CDB-2914 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 at 200 mg
Study: 12923133
Drug: CDB-2914 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 at doses of 10, 50, 100 and 200 mg
Study: 12212206
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg.d-1
Study: 20876317
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy followed by postoperative chemotherapy
Study: 18361816
Drug: Block +
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Block + manipulation treatment (Group I)
Study: 10994616
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. for 2 weeks
Study: 8772566
Drug: Episodic GHRH
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic GHRH administration (200 micrograms, 4 boluses of 50 micrograms each at 2200, 2300, 2400, and 0100 h)
Study: 8772566
Drug: Continuous GHRH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous GHRH infusion (57 micrograms/h between 2130 and 0100 h)
Study: 3158254
Drug: Atracurium steady-state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium steady-state infusion during halothane or isoflurane anesthesia
Study: 3158254
Drug: Atracurium steady-state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium steady-state infusion during balanced anesthesia
Study: 26673811
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg daily)
Study: 26673811
Drug: Temsirolimus (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75 mg on days 1, 8, and 15 of subsequent cycles)
Study: 18522727
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of cognac (1.2 +/- 0.1 dl)
Study: 18522727
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of cognac (2.4 +/- 0.3 dl)
Study: 10050702
Drug: enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin (40 mg, 4000 anti-Xa IU)
Study: 7486040
Drug: Thiamylal (4.0‐5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal (4.0‐5.0 mg/kg)
Study: 7486040
Drug: Ketamine (1.5‐2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1.5‐2.0 mg/kg)
Study: 7486040
Drug: Succinylcholine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1.0 mg/kg) - Control Group O